| Identification | Back Directory | [Name]
Mavorixafor trihydrochloride | [CAS]
2309699-17-8 | [Synonyms]
AMD-070 trihydrochloride
Mavorixafor trihydrochloride | [Molecular Formula]
C21H28ClN5 | [MOL File]
2309699-17-8.mol | [Molecular Weight]
385.94 |
| Hazard Information | Back Directory | [Uses]
Mavorixafor trihydrochloride (AMD-070 trihydrochloride) is a potent, selective and orally available CXCR4 antagonist, with an IC50 value of 13 nM against CXCR4 125I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC50 of 1 and 9 nM, respectively.Mavorixafor trihydrochloride can be used for the study of WHIM syndrome[1]. | [in vivo]
Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss[2]. | [IC 50]
125I-SDF-CXCR4: 13 nM (IC50); HIV-1 (NL4.3 strain): 1 nM (IC50, in MT-4 cells); HIV-1 (NL4.3 strain): 9 nM (IC50, in PBMCs); HIV-1 (NL4.3 strain): 3 nM (IC90, in MT-4 cells); HIV-1 (NL4.3 strain): 26 nM (IC90, in PBMCs) | [storage]
Store at -20°C | [References]
[1] Skerlj RT, et al. Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication. J Med Chem. 2010 Apr 22;53(8):3376-88. DOI:10.1021/jm100073m
[2] Uchida D, et al. Effect of a novel orally bioavailable CXCR4 inhibitor, AMD070, on the metastasis of oral cancer cells. Oncol Rep. 2018 Jul;40(1):303-308. DOI:10.3892/or.2018.6400 |
|
| Company Name: |
cjbscvictory
|
| Tel: |
13348960310 |
| Website: |
https://www.weikeqi-biotech.com/ |
| Company Name: |
MedChemExpress
|
| Tel: |
021-58955995 |
| Website: |
www.medchemexpress.com |
|